SE9600647D0 - Ny användning - Google Patents

Ny användning

Info

Publication number
SE9600647D0
SE9600647D0 SE9600647A SE9600647A SE9600647D0 SE 9600647 D0 SE9600647 D0 SE 9600647D0 SE 9600647 A SE9600647 A SE 9600647A SE 9600647 A SE9600647 A SE 9600647A SE 9600647 D0 SE9600647 D0 SE 9600647D0
Authority
SE
Sweden
Prior art keywords
mucous membranes
new use
protein
tropism
immunogen
Prior art date
Application number
SE9600647A
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein, Bengtsson Karin Loevgren, Jill Ekstroem filed Critical Bror Morein
Priority to SE9600647A priority Critical patent/SE9600647D0/sv
Publication of SE9600647D0 publication Critical patent/SE9600647D0/sv
Priority to EP97905541A priority patent/EP0889736B1/en
Priority to DE69726712T priority patent/DE69726712T2/de
Priority to AT97905541T priority patent/ATE255905T1/de
Priority to CA002247522A priority patent/CA2247522C/en
Priority to ES97905541T priority patent/ES2210495T3/es
Priority to PCT/SE1997/000289 priority patent/WO1997030728A1/en
Priority to JP9530070A priority patent/JP2000504746A/ja
Priority to NZ331403A priority patent/NZ331403A/en
Priority to AU22385/97A priority patent/AU719084B2/en
Priority to DK97905541T priority patent/DK0889736T3/da
Priority to US09/137,236 priority patent/US6607732B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SE9600647A 1996-02-21 1996-02-21 Ny användning SE9600647D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9600647A SE9600647D0 (sv) 1996-02-21 1996-02-21 Ny användning
DK97905541T DK0889736T3 (da) 1996-02-21 1997-02-20 Iscom eller iscom-matrix, der omfatter et stof, der retter sig mod mucus, og et antigen
CA002247522A CA2247522C (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
DE69726712T DE69726712T2 (de) 1996-02-21 1997-02-20 Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
AT97905541T ATE255905T1 (de) 1996-02-21 1997-02-20 Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
EP97905541A EP0889736B1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and an antigen
ES97905541T ES2210495T3 (es) 1996-02-21 1997-02-20 Iscom o matriz de iscom que comprende una sustancia dirigida especificamente a las mucosas y un antigeno.
PCT/SE1997/000289 WO1997030728A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
JP9530070A JP2000504746A (ja) 1996-02-21 1997-02-20 粘液ターゲティング物質、および抗原を随時含むイスコムまたはイスコム―マトリックス
NZ331403A NZ331403A (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
AU22385/97A AU719084B2 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
US09/137,236 US6607732B2 (en) 1996-02-21 1998-08-20 ISCOM or ISCOM-matrix comprising a mucous targetting substance and an antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600647A SE9600647D0 (sv) 1996-02-21 1996-02-21 Ny användning

Publications (1)

Publication Number Publication Date
SE9600647D0 true SE9600647D0 (sv) 1996-02-21

Family

ID=20401481

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600647A SE9600647D0 (sv) 1996-02-21 1996-02-21 Ny användning

Country Status (12)

Country Link
US (1) US6607732B2 (sv)
EP (1) EP0889736B1 (sv)
JP (1) JP2000504746A (sv)
AT (1) ATE255905T1 (sv)
AU (1) AU719084B2 (sv)
CA (1) CA2247522C (sv)
DE (1) DE69726712T2 (sv)
DK (1) DK0889736T3 (sv)
ES (1) ES2210495T3 (sv)
NZ (1) NZ331403A (sv)
SE (1) SE9600647D0 (sv)
WO (1) WO1997030728A1 (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
PL1838341T3 (pl) 2005-01-20 2014-04-30 Isconova Ab Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
CN107693787A (zh) 2007-09-04 2018-02-16 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 轮状病毒的热灭活
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
WO2012011868A1 (en) 2010-07-23 2012-01-26 Osterhaus A D M E Influenza vaccine
MX352604B (es) 2011-05-13 2017-11-30 Zoetis Llc Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
ES2673957T5 (es) 2011-10-03 2021-12-15 Croda Int Plc Nanopartículas, procedimiento para la preparación y utilización de las mismas como portadoras de moléculas anfipáticas o hidrofóbicas en el campo de la medicina, incluyendo el tratamiento del cáncer, y compuestos de tipo alimentario
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
MX2016007870A (es) 2013-12-16 2016-10-07 Zoetis Services Llc Composiciones inmunogenas de glucoproteina g de los virus hendra y nipah.
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection

Also Published As

Publication number Publication date
DK0889736T3 (da) 2004-04-19
NZ331403A (en) 2000-02-28
DE69726712T2 (de) 2004-10-07
EP0889736A1 (en) 1999-01-13
AU2238597A (en) 1997-09-10
JP2000504746A (ja) 2000-04-18
CA2247522C (en) 2009-12-29
ATE255905T1 (de) 2003-12-15
ES2210495T3 (es) 2004-07-01
DE69726712D1 (de) 2004-01-22
US20020131982A1 (en) 2002-09-19
WO1997030728A1 (en) 1997-08-28
CA2247522A1 (en) 1997-08-28
US6607732B2 (en) 2003-08-19
EP0889736B1 (en) 2003-12-10
AU719084B2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
SE9600647D0 (sv) Ny användning
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE69019164D1 (de) Verbessertes meningokokkale polysaccharidkonjugatvakzin.
EP0955059A3 (en) Vaccines containing a saponin and a sterol
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
BR9814483A (pt) "vacina"
NO991524L (no) Vaksiner
BR0014282A (pt) Vacinas
CY1107457T1 (el) Εμβoλιο κατa του hpv
NO982497D0 (no) Vaksine-sammensetninger for inntak gjennom nesen
MX9203808A (es) Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
TR199501635A1 (tr) Solunum yolu ile alinan terapötik preparatlar.
AU8113591A (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
EP0979080A4 (en) METHOD FOR MODULATING THE IMMUNE REACTION IN AN INFECTIVE MAMMALIAN BY THE TRANSMUCOSAL ENTERING A MODULATING AGENT
NO972219D0 (no) Immunogenpreparater
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
FI915702A0 (fi) Peptider och daerav erhaollna antikroppar foer diagnos av vaccination emot htlv-1 infektion.
FR2715304B1 (fr) Vaccin anti-allergique.
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
WO2001034185A3 (en) Induction of mucosal immunity by vaccination via the skin route
EP0584212A4 (en) LIPOSOMAL POLYSACCHARID VACCINE.
WO2001037862A3 (en) A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
ES2082221T3 (es) Neuraminidasa y galactosa-oxidasa en calidad de adyuvante de vacunas.
AU1825895A (en) Retroviral vaccines, vaccination and immune-therapy for retroviral infections